Palvella Therapeutics (PVLA) Invested Capital (2016 - 2024)
Historic Invested Capital for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to -$87.4 million.
- Palvella Therapeutics' Invested Capital fell 38647.66% to -$87.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$87.4 million, marking a year-over-year decrease of 38647.66%. This contributed to the annual value of -$74.5 million for FY2023, which is 36668.7% down from last year.
- As of Q3 2024, Palvella Therapeutics' Invested Capital stood at -$87.4 million, which was down 38647.66% from -$80.8 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Invested Capital ranged from a high of $53.9 million in Q3 2021 and a low of -$87.4 million during Q3 2024
- Moreover, its 5-year median value for Invested Capital was $38.2 million (2021), whereas its average is $15.2 million.
- As far as peak fluctuations go, Palvella Therapeutics' Invested Capital skyrocketed by 13952.78% in 2020, and later tumbled by 59730.24% in 2024.
- Over the past 5 years, Palvella Therapeutics' Invested Capital (Quarter) stood at $31.0 million in 2020, then surged by 63.58% to $50.8 million in 2021, then plummeted by 44.97% to $27.9 million in 2022, then tumbled by 366.69% to -$74.5 million in 2023, then fell by 17.35% to -$87.4 million in 2024.
- Its Invested Capital stands at -$87.4 million for Q3 2024, versus -$80.8 million for Q2 2024 and -$76.9 million for Q1 2024.